A Biofabrication Strategy for a Custom-Shaped, Non-Synthetic Bone Graft Precursor with a Prevascularized Tissue...

Craniofacial reconstruction often involves complex bone defects that are difficult to repair using traditional methods. Current gold-standard grafts come with limitations like donor-site complications and limited availability. While synthetic grafts have been explored, they lack biological integration and may not fully replicate natural bone healing. Researchers have sought alternatives that are customizable, biologically active, and free of synthetic materials. Recent advancements in biofabrication have enabled the development of patient-specific grafts. However, the challenge remains to create grafts that support vascularization and osteogenesis. Prior studies have shown that vascularized tissue layers can enhance graft integration. Yet, few studies have combined bioprinting with pre-vascularized tissue shells for bone grafting. This gap motivated the development of a graft that integrates bioprinted bone matrix with a vascularized tissue layer.

The study aimed to develop a novel bone graft strategy for craniofacial reconstruction. The goal was to create a graft that is tailored to the patient’s anatomy and defect shape. The approach avoids synthetic materials and instead uses biologically derived components. The graft was designed to include a cellularized bone matrix and a pre-vascularized tissue shell. The objective was to test whether this graft could promote vascularization and bone formation in an animal model. The study also aimed to demonstrate a workflow that could be implemented in a hospital setting. The researchers hypothesized that the graft’s design would enhance engraftment and mechanical strength. This approach could potentially reduce the need for donor-site harvesting and improve graft outcomes.

The research team created a graft using bioprinting techniques and human-derived materials. They blended demineralized bone matrix with native matrix proteins to form the graft core. Human mesenchymal stromal cells were incorporated into the matrix to support osteogenesis. The graft was then encased in a tissue shell made from isolated human adipose microvessels. These microvessels were selected for their potential to promote vascularization. The graft was implanted in rats to assess its performance in vivo. The study monitored vascularization and ossification over time using imaging and histological analysis. The team also evaluated the mechanical strength of the graft post-implantation to determine its functional viability.

The graft demonstrated successful ossification in rats following implantation. Vascularization occurred both within and around the graft, forming a vascular leash that supported tissue integration. The pre-vascularized tissue shell contributed to early vascularization, which is critical for graft survival. Histological analysis confirmed the presence of new bone formation within the graft structure. The graft showed mechanical strength comparable to native bone tissue. The bioprinted matrix retained its shape and supported cell activity throughout the healing process. No synthetic materials were used in the graft’s composition, aligning with the study’s objective. These findings suggest that the graft design is feasible for future clinical applications.

The study demonstrated the feasibility of a biofabrication strategy for a patient-specific bone graft. The graft’s design, which includes a bioprinted matrix and a pre-vascularized tissue shell, supports vascularization and bone formation. The absence of synthetic materials is a key advantage for clinical translation. The graft’s performance in rats suggests potential for use in craniofacial reconstruction. The workflow is designed for hospital-based fabrication near the Point of Care, improving accessibility. The results align with the authors’ hypothesis that vascularization enhances engraftment. The graft’s mechanical strength and shape retention support its functional viability. These findings represent a step toward a biologically active graft that could reduce donor-site complications.